Pharmafile Logo
  • - PMLiVE
  • - PMLiVE
  • Diversity, Equity and Inclusion
  • Communiqué 53 Cover Image

    • Outsourcing

    - PMLiVE

    BMS, Takeda and Astex join AI training consortium

    The initiative focuses on training AI models to aid in drug discovery and development

    Streamline Clinical Trial Collaboration – Engaging Your Advisors Creatively

    Boost efficiency in clinical operations! Learn a creative way to enhance communication between teams at different sites and streamline the development of study protocols, support materials, and journal submissions.

    Impetus Digital

    market access in Japan

    Implementation of Cost-Effectiveness Analysis in Japan’s Health Technology Assessment Process

    Japan’s evolving approach to market access includes a formal cost-effectiveness analysis (CEA) requirement for certain new medicines and medical devices. Introduced as part of a broader health technology assessment (HTA)...

    Petauri Evidence

    - PMLiVE

    Takeda receives EC approval for Adcetris combination in Hodgkin lymphoma

    The decision marks the second approval for an Adcetris-based regimen for front-line Hodgkin lymphoma

    - PMLiVE

    BioNTech announces £1bn UK investment to boost regional R&D presence

    The UK government has also agreed to award the company a grant of up to £129m

    - PMLiVE

    Sanofi unveils $20bn US investment to boost R&D and manufacturing presence

    The company is the latest major drugmaker to announce a significant investment in the country

    - PMLiVE

    Takeda’s Adzynma approved by MHRA for rare blood clotting disorder cTTP

    The enzyme replacement therapy is now the first treatment approved in the UK for this patient population

    - PMLiVE

    Takeda receives CHMP recommendation for Adcetris in Hodgkin lymphoma

    The EC will review the committee’s positive opinion as it makes a decision on Adcetris in this indication

    - PMLiVE

    Takeda receives NICE recommendation for Adcetris combination in Hodgkin lymphoma

    Around 800 people in the UK are diagnosed with late-stage disease every year

    - PMLiVE

    Johnson & Johnson to invest more than $55bn in US over next four years

    The commitment marks a 25% increase to the company's US investments in the past four years

    - PMLiVE

    Takeda/Protagonist share positive phase 3 results for rusfertide in rare blood cancer

    Up to 160,000 people in the US are affected by polycythaemia vera

    - PMLiVE

    Takeda and EU Innovative Health Initiative launch Crohn’s disease prevention study

    Approximately three million people in Europe are affected by inflammatory bowel disease

    Subscribe to our email news alerts

    Latest content

    Latest intelligence

    Quick links